Across TCGA pan-cancer cohorts, RNY4P17 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RNY4P17’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where RNY4P17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNY4P17 is over-expressed in tumor.

STAD and ESCA are the cancer types where RNY4P17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNY4P17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	Male	II,III,IV	+0.489	.024	4	view →
ESCA	Female	All	+0.650	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RNY4P17 RNA expression & survival · all RNY4P17 data types